MIRA
INFORM REPORT
|
Report Date : |
18.12.2007 |
IDENTIFICATION
DETAILS
|
Name : |
RIKAKEN CO LTD |
|
|
|
|
Registered Office : |
2-107 Motogo Moriyamaku Nagoya 463-0025 |
|
|
|
|
Country : |
Japan |
|
|
|
|
Financials (as on) : |
30.09.2007 |
|
|
|
|
Date of Incorporation : |
Jul 1977 |
|
|
|
|
Legal Form : |
Limited Company (Kabushiki Kaisha) |
|
|
|
|
Line of Business : |
Import, wholesale of reagents, lab
& clinical test equipment |
RATING &
COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
Yen 232.3 millions |
|
|
|
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Regular |
name
RIKAKEN CO LTD
REGD NAME
Rikaken KK
MAIN OFFICE
2-107 Motogo Moriyamaku Nagoya 463-0025 JAPAN
Tel : 052-798-6151
Fax : 052-798-6157
URL : http://www.rikaken.co.jp
E-mail :
honsha@rikaken.co.jp
ACTIVITIES
Import, wholesale of reagents, lab & clinical test
equipment
BRANCHES
Gifu, Mie, Yokkaichi, Shizuoka, Tokyo, Tsukuba, Kashiwa,
Yokohama, Tsurumi
OFFICERS
YOSHIO MORIKAWA, PRES Yuji
Nishikawa, s/mgn dir
Katsumi Yokochi, mgn dir Hideshige
Kawahara, mgn dir
Toshikazu Awaya, mgn dir
Yen Amount: In
million Yen, unless otherwise stated
SUMMARY
FINANCES FAIR A/SALES Yen 15,200 M
PAYMENTS REGULAR CAPITAL Yen 30 M
TREND STEADY WORTH Yen 1,794 M
STARTED 1977 EMPLOYES 201
COMMENT
IMPORTER & WHOLESALER SPECIALIZING IN REAGENTS & LAB
EQUIPMENT. FINANCIAL SITUATION
CONSIDERED FAIR AND GOOD FOR ORDINARY BUSINESS ENGAGEMENTS.
MAX CREDIT LIMIT: YEN 232.3 MILLION, 30 DAYS NORMAL
TERMS.
HIGHLIGHTS
The subject company was established by Yoshio Morikawa in order
to make most of his experience in the subject line of business. This is a trading firm specializing in import
and wholesale of general chemical reagents, clinical test medicines, lab &
clinical test equipment, other. Also
handles DNA customer synthesis. Clients
are universities, laboratories, clinical institutions, other nationwide.
FINANCIAL INFORMATION
The firm does not disclose full financials and only partially for Sept/2006 term in digest form.
The sales volume for Sept/2006 fiscal term amounted to Yen 15,200 million, a 5% down from Yen 15,923 million in the previous term. The net profit was posted at Yen 170 million, down from Yen 173 million a year ago.
For the term ended Sept 2007 the net profit is believed posted
at Yen 171 million, on a slight rise in turnover, to Yen 15,300 million. Final results are yet to be released.
The financial situation is considered maintained FAIR and good
for ORDINARY business engagements. Max
credit limit is estimated at Yen 232.3 million, on 30 days normal terms.
REGISTRATION
Date Registered: Jul
1977
Legal Status: Limited
Company (Kabushiki Kaisha)
Regd No: 1899-01-033403
Authorized: 240,000
shares
Issued: 60,000
shares
Sum: Yen
30 million
Major shareholders (%): Yoshio
Morikawa (35), Saburo Hattori (13), Yoko Morikawa (12)
No. of shareholders: 7
Nothing detrimental is known as to the commercial morality
of executives.
OPERATION
Activities: Imports and wholesales general chemical reagents,
clinical test medicines, lab equipment, clinical test equipment; DNA customer synthesis
undertaken by Rikaken Laboratory Station (--100%).
Clients: [Universities, laboratories] Nagoya Univ, Nagoya City College, Univ of Tokyo, Fujita Health Univ, National Institute of Nature Science, other.
No. of accounts: 300
Domestic areas of activities: Nationwide
Suppliers: [Mfrs, wholesalers] Wako Pure Chemical Ind, GE
Healthcare Bioscience, Hitachi High Technologies, M&S Instruments Inc,
Takara Bio Inc, other.
Payment record: Regular
Location: Business area in Nagoya. Office premises at the caption address are leased and maintained
satisfactorily.
Bank References
Mie Bank (Imaike)
SMBC (Motoyama)
Relations: Satisfactory
FINANCES
(In Million Yen)
|
Terms Ending: |
30/09/2007 |
30/09/2006 |
30/09/2005 |
30/09/2004 |
|
|
Annual Sales |
|
15,300 |
15,200 |
15,923 |
16,800 |
|
Recur. Profit |
|
|
|
|
|
|
Net Profit |
|
171 |
170 |
173 |
299 |
|
Total Assets |
|
|
6,892 |
|
|
|
Current Assets |
|
|
5,083 |
|
|
|
Current Liabs |
|
|
4,809 |
|
|
|
Net Worth |
|
|
1,794 |
|
|
|
Capital, Paid-Up |
|
|
30 |
30 |
30 |
|
Div.P.Share(¥) |
|
|
0.00 |
0.00 |
0.00 |
|
<Analytical Data> |
(%) |
(%) |
(%) |
(%) |
|
|
S.Growth Rate |
0.66 |
-4.54 |
-5.22 |
4.00 |
|
|
Current Ratio |
|
.. |
105.70 |
.. |
.. |
|
N.Worth Ratio |
.. |
26.03 |
.. |
.. |
|
|
R.Profit/Sales |
|
.. |
.. |
.. |
.. |
|
N.Profit/Sales |
1.12 |
1.12 |
1.09 |
1.78 |
|
|
Return On Equity |
.. |
9.48 |
.. |
.. |
|
Notes: Financials are only partially disclosed, except for
the 30/09/2006 fiscal term.
Forecast (or estimated) for the 30/09/2007 fiscal term.
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit consideration.
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)